Determinants of discontinuation of new courses of antihypertensive medications

被引:54
作者
Grégoire, JP [1 ]
Moisan, J
Guibert, R
Ciampi, A
Milot, A
Gaudet, M
Côté, I
机构
[1] Univ Laval, Fac Pharm, Quebec City, PQ, Canada
[2] Univ Laval, Unite Rech & St Populat, Quebec City, PQ, Canada
[3] Merck Frosst Canada Ltd, Quebec City, PQ 49H 3L1, Canada
[4] Mornington Peninsular Div Gen Pract, Frankston, Australia
[5] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[6] Univ Laval, Fac Med, Dept Med, Quebec City, PQ G1K 7P4, Canada
[7] Univ Laval, Fac Med, Dept Med, Quebec City, PQ, Canada
[8] Univ Laval, Unite Rech & St Populat, Quebec City, PQ, Canada
[9] Inst Hlth Econ, Edmonton, AB, Canada
关键词
discontinuation; determinants; compliance; drug treatment; hypertension;
D O I
10.1016/S0895-4356(02)00400-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Discontinuation of medication use constitutes a major barrier to adequate control of high blood pressure. We examined the effect of an array of potential predisposing, enabling and reinforcing factors on the discontinuation of newly prescribed antihypertensive medications. We conducted a prospective cohort study through a network of 173 pharmacies across Canada where were identified individuals newly prescribed an antihypertensive monotherapy. We interviewed participants by telephone four times to obtain information for a minimum duration of 18 months after entry into the cohort. We analyzed data using a multivariate proportional hazard model. Of 682 eligible participants, 43.3% had discontinued their initial medication at the end of the observation period. Individuals more likely to discontinue their initial medication were those who perceived side effects from this medication [Hazard Ratio (HR) = 1.91: 95% Confidence Interval (CI) 1.47-2.47). Individuals kith medication insurance coverage were less likely to discontinue (HR = 0.74: 95% CI 0.55-0.99). Persistence with newly prescribed medications could be improved by selecting antihypertensive medications containing fewer side effects and by lifting economic barrier, to drug treatment. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:728 / 735
页数:8
相关论文
共 27 条
  • [1] Persistence of use of lipid-lowering medications - A cross-national study
    Avorn, J
    Monette, J
    Lacour, A
    Bohn, RL
    Monane, M
    Mogun, H
    LeLorier, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18): : 1458 - 1462
  • [2] Blood pressure in Spain -: Distribution, awareness, control, and benefits of a reduction in average pressure
    Banegas, JR
    Rodríguez-Artalejo, F
    Troca, JJD
    Guallar-Castillón, P
    Calero, JD
    [J]. HYPERTENSION, 1998, 32 (06) : 998 - 1002
  • [3] BECKER MH, 1981, COMBINING PSYCHOL DR, P67
  • [4] Belsley D.A., 1980, Regression Diagnostics: Identifying Influential Data and Sources of Collinearity
  • [5] Continuation of initial antihypertensive medication after 1 year of therapy
    Bloom, BS
    [J]. CLINICAL THERAPEUTICS, 1998, 20 (04) : 671 - 681
  • [6] Caro JJ, 1999, CAN MED ASSOC J, V160, P31
  • [7] Caro JJ, 1999, CAN MED ASSOC J, V160, P41
  • [8] CURB J D, 1985, American Journal of Preventive Medicine, V1, P36
  • [9] SAFETY AND TOLERABILITY OF LOSARTAN POTASSIUM, AND ANGIOTENSIN-II RECEPTOR ANTAGONIST, COMPARED WITH HYDROCHLOROTHIAZIDE, ATENOLOL, FELODIPINE ER, AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS FOR THE TREATMENT OF SYSTEMIC HYPERTENSION
    GOLDBERG, AI
    DUNLAY, MC
    SWEET, CS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (12) : 793 - 795
  • [10] GREEN IW, 1991, HLTH PROMOTION PLANN